Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Bio-Techne (TECH) Long-Term Deferred Tax (2025)

Bio-Techne has reported Long-Term Deferred Tax over the past 3 years, most recently at $10.3 million for Q2 2025.

For Q2 2025, Long-Term Deferred Tax changed N/A year-over-year to $10.3 million; the TTM value through Jun 2025 reached $10.3 million, changed N/A, while the annual FY2025 figure was $10.3 million, N/A changed from the prior year.
Long-Term Deferred Tax for Q2 2025 was $10.3 million at Bio-Techne, up from $539000.0 in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $10.3 million in Q2 2025 and troughed at $10.3 million in Q2 2025.